AU2011331901B2 - Anti-inflammatory compositions - Google Patents

Anti-inflammatory compositions Download PDF

Info

Publication number
AU2011331901B2
AU2011331901B2 AU2011331901A AU2011331901A AU2011331901B2 AU 2011331901 B2 AU2011331901 B2 AU 2011331901B2 AU 2011331901 A AU2011331901 A AU 2011331901A AU 2011331901 A AU2011331901 A AU 2011331901A AU 2011331901 B2 AU2011331901 B2 AU 2011331901B2
Authority
AU
Australia
Prior art keywords
interleukin
administration
inflammatory
inflammation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011331901A
Other languages
English (en)
Other versions
AU2011331901A1 (en
Inventor
Sai Ying Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolingus Ip Ii GmbH
Original Assignee
Biolingus Ip Ii GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolingus Ip Ii GmbH filed Critical Biolingus Ip Ii GmbH
Publication of AU2011331901A1 publication Critical patent/AU2011331901A1/en
Application granted granted Critical
Publication of AU2011331901B2 publication Critical patent/AU2011331901B2/en
Assigned to BIOLINGUS IP LLC reassignment BIOLINGUS IP LLC Request for Assignment Assignors: KO, SAI
Assigned to BioLingus IP II GmbH reassignment BioLingus IP II GmbH Request for Assignment Assignors: BIOLINGUS IP LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
AU2011331901A 2010-11-19 2011-11-09 Anti-inflammatory compositions Ceased AU2011331901B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8 2010-11-19
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
AU2011331901A1 AU2011331901A1 (en) 2013-04-18
AU2011331901B2 true AU2011331901B2 (en) 2015-01-22

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011331901A Ceased AU2011331901B2 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Country Status (12)

Country Link
US (1) US9289493B2 (enExample)
EP (1) EP2640411B1 (enExample)
JP (1) JP2013544244A (enExample)
KR (1) KR101989201B1 (enExample)
CN (1) CN102462837B (enExample)
AU (1) AU2011331901B2 (enExample)
CA (1) CA2817996C (enExample)
DK (1) DK2640411T3 (enExample)
MX (1) MX348794B (enExample)
MY (1) MY174797A (enExample)
RU (1) RU2627451C9 (enExample)
WO (1) WO2012065212A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
EP3443979B2 (en) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
KR102499727B1 (ko) * 2015-02-25 2023-02-15 아웃센스 다이아그나스틱스 엘티디. 신체 배출물 분석
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
RU2021101120A (ru) * 2016-09-15 2022-03-16 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
AR121713A1 (es) 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018992A1 (en) * 1997-10-10 1999-04-22 Pharma Pacific Pty. Ltd. Oromucosal cytokine compositions and uses thereof
US20030135887A1 (en) * 1996-10-18 2003-07-17 The Minister Of Agriculture & Agri-Food Canada, London Health Sciences Center Plant bioreactors
WO2004024125A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
WO2008109953A1 (en) * 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ｉｌ−６を含む血清尿酸値低下剤
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030135887A1 (en) * 1996-10-18 2003-07-17 The Minister Of Agriculture & Agri-Food Canada, London Health Sciences Center Plant bioreactors
WO1999018992A1 (en) * 1997-10-10 1999-04-22 Pharma Pacific Pty. Ltd. Oromucosal cytokine compositions and uses thereof
WO2004024125A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
WO2008109953A1 (en) * 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SLAVIN AJ, et al., International Immunology, (2001), Vol 13, No 6, pp 825-833. *

Also Published As

Publication number Publication date
CN102462837A (zh) 2012-05-23
CA2817996A1 (en) 2012-05-24
JP2013544244A (ja) 2013-12-12
MX348794B (es) 2017-06-29
RU2627451C2 (ru) 2017-08-08
KR20140009262A (ko) 2014-01-22
CN102462837B (zh) 2016-08-03
MX2013005641A (es) 2014-02-06
EP2640411B1 (en) 2017-12-20
MY174797A (en) 2020-05-15
CA2817996C (en) 2019-10-15
RU2013127793A (ru) 2014-12-27
EP2640411A1 (en) 2013-09-25
US9289493B2 (en) 2016-03-22
KR101989201B1 (ko) 2019-06-13
AU2011331901A1 (en) 2013-04-18
WO2012065212A1 (en) 2012-05-24
DK2640411T3 (en) 2018-04-03
EP2640411A4 (en) 2013-11-20
US20130315859A1 (en) 2013-11-28
RU2627451C9 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
US9289493B2 (en) Method for treating inflammatory conditions with mucosally administered interleukin-2
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
US20180153776A1 (en) Application and uses of prg4 and therapeutic modulation thereof
EP2628484A1 (en) Platelet-rich plasma compositions
JP2005503340A (ja) 口腔および食道病変の治療のための方法および組成物
KR930002010B1 (ko) 당뇨병 치료제
US20140162948A1 (en) Formulation for increasing bioavailability of neurturin
TW200538466A (en) Methods for controlling angiogenesis and cell proliferation
Kwan et al. Short-term administration of SMS 201-995 in the management of an external pancreatic fistula.
JP4912306B2 (ja) ヒトｉｌ−１８を投与することによって創傷を治癒する方法
AU2008226337B2 (en) Method for treating cancer via the mucosal administration of interleukin
WO2015170286A2 (en) Modulation of blood glucose levels
JP4914344B2 (ja) 虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
WO2020058827A1 (en) Oral transmucosal immunotherapy
JP2875541B2 (ja) 血行再建術後の再閉塞防止剤
JPH07215892A (ja) 突発性難聴治療用医薬組成物
JP2007511540A (ja) 肥満の処置のためおよび体重減少の促進のためのインターフェロンτの使用
CN115252621A (zh) 一种小分子化合物在制备治疗骨关节炎药物中的应用
EP1842858A2 (en) Methods and compositions for treating oral and esophageal lesions
CN1929854A (zh) 肺泡的分化诱导或再生诱导制剂
HK1137949A (en) Methods of healing wounds by administering human il-18
HK1109742A (en) Methods and compositions for treating oral and esophageal lesions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BIOLINGUS IP LLC

Free format text: FORMER OWNER WAS: KO, SAI

PC Assignment registered

Owner name: BIOLINGUS IP II GMBH

Free format text: FORMER OWNER(S): BIOLINGUS IP LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired